Tetra Pharm Technologies ApS

Egen beskrivelse på virk.dk

Description of key activities of the companyTetra Pharm Technologies is a Danish biopharmaceutical company founded in 2018 that specializes in the development of pharmaceutical drugs aimed at the central nervous system and the immune system to treat neurological diseases and mental health disorders. About Tetra Pharm TechnologiesTetra Pharm Technologies is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Copenhagen, Denmark, specialized in developing pharmaceutical drugs targeting the central nervous system and the immune system to treat neurological diseases and mental health disorders. Tetra Pharm Tetra Pharm Technologies operates across three tightly integrated pillars: Proprietary Drug Delivery Platforms (ZYNDIKATE®) Platform-Based R&D PipelineCommercial CDMO Services Unlike traditional biotechnology companies that depend on the success of a single molecule, Tetra Pharm Technologies operates as an integrated pharmaceutical operating system. The R&D pipeline spans neurology, psychiatry, inflammation, and metabolic disease, with lead candidates targeting chronic pain, Alzheimer's disease, and obesity. In addition, Tetra Pharm Technologies offers a suite of tailored end-to-end CDMO (Contract Development and Manufacturing Organisation) services, including drug formulation, drug delivery, testing and validation, and manufacturing and market consultancy.The two business segments complement each other seamlessly, both leveraging the company's proprietary drug delivery technology, ZYNDIKATE®. This synergy enables a balanced model, where the CDMO business generates revenue that can be reinvested into further developing the clinical pipeline. Highlights in 2025 Tetra Pharm Technologies made significant progress advancing several pipeline drug candidates, including initiating Phase 1 clinical trials for its lead candidate targeting chronic pain, TPT0301. The company also advanced TPT0026, targeting obesity, through preclinical trials, with the candidate now ready to enter Phase 1 clinical trials. To support its growth strategy within the CDMO segment, Tetra Pharm Technologies relocated to newly established EU-GMP-certified manufacturing facilities. In parallel, the company initiated negotiations with prospective customers across multiple international markets. Protection of intellectual property is of highest priority for Tetra Pharm Technologies. During the year, the company submitted a number of patent and trademark applications with the European Patent Organization. Internally, Tetra Pharm Technologies strengthened the organization to support future development and the long term strategy of company, and recruited a number of other key employees, which brings the total number of employees to 47 at year-end. Long-term objectivesThe primary objective for the coming years is to continue advancing the company's drug candidates into preclinical and clinical trials. In addition, Tetra Pharm Technologies aim to significantly grow its revenue-generating CDMO business segment across new geographies to support the ongoing development of its clinical pipeline.